Pasithea Therapeutics names Kartik Krishnan chief medical officer
PUBT · 05/04 11:05
Share
Listen to the news
- Pasithea Therapeutics appointed Kartik Krishnan as chief medical officer, effective May 1, 2026.
- Krishnan will lead clinical development and medical strategy as PAS-004 advances in neurofibromatosis type 1 associated plexiform and cutaneous neurofibromas.
- He was previously CEO of OncoNano Medicines, following a stint as CMO at Arcus Biosciences.
- Earlier roles included clinical development and medical leadership positions at Genentech, BioMarin, Amgen, Astex Pharmaceuticals, and Five Prime Therapeutics.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pasithea Therapeutics Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605040701PRIMZONEFULLFEED9711985) on May 04, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending